Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 457 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SBRT Clear all

Conditions: Pleural Mesothelial Neoplasm
Interventions: Immunotherapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy; Other · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Computed Tomography, Stereotactic Body Radiation Therapy; Procedure · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Spinal Metastases
Interventions: qMRI with Gadoteridol contrast agent; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions: stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis; Radiation · Procedure · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer, Localized Prostate Carcinoma
Interventions: Microboost SBRT, Whole gland de-escalation 30 Gy, Whole gland de-escalation 35 Gy; Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Early Stage Prostate Cancer
Interventions: Hypofractionated Radiation; Radiation
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Metastatic Clear Cell Renal Cell Carcinoma
Interventions: IL-2, Stereotactic Ablative Body Radiation Therapy; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatocellular Carcinoma, HCC
Interventions: Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin; Radiation · Procedure · Drug
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Recurrent Head and Neck Carcinoma
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Cancer, Metastatic Lung Cancer
Interventions: Stereotactic Body Radiotherapy (SBRT); Radiation
Lead sponsor: The Netherlands Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Royal Oak, Michigan • Philadelphia, Pennsylvania

Conditions: Pancreatic Adenocarcinoma
Interventions: PCX-12; Drug
Lead sponsor: Haoming (Carl) Qiu; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Non Small Cell Lung Cancer
Interventions: Pembrolizumab, stereotactic radiation therapy (SRT), Surgery (Non-interventional, standard of care); Drug · Radiation · Procedure
Lead sponsor: Sue Yom; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cancer of Lung
Interventions: AIP CT, FB (Free-Breathing) CT; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal, Liver Metastases
Interventions: Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Interventions: stereotactic radiosurgery, therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment; Radiation · Procedure · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: 5 Fraction Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Clear Cell Renal Cell Carcinoma
Interventions: Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Benign Prostatic Hyperplasia
Interventions: Urolift; Device
Lead sponsor: Northwell Health; Other
Eligibility: 50 Years to 99 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Syosset, New York

Conditions: Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions: stereotactic body radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis; Radiation · Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Bone Metastases
Interventions: Radiation Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy, Thoracic Surgical Procedure; Other · Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Vertebral Metastasis
Interventions: Stereotactic Radiation Therapy, SRT with Vertebral Augmentation Procedure; Radiation
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Lung Cancer, Oligometastatic Lung Tumor
Interventions: One fraction stereotactic body radiotherapy, HyperSight, Ethos; Radiation · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Childhood Solid Tumor, Childhood Lymphoma, Relapsed Cancer, Refractory Cancer, Adult Solid Tumor, Adult Lymphoma
Interventions: Pembrolizumab, Decitabine, Hypofractionated Index Site Radiation; Drug · Radiation
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Months to 40 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma

Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors

Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases

High-Dose Stereotactic Radiation for Prostate Cancer

MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer

Ultra-hypofractionated Radiation in Prostate Cancer

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant

Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer

Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously

Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)

Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer

4D CBCT and Intrafractional Imaging for the Determination of the Most Representative 4D Simulation Planning Technique for Lung SBRT Technique Patients

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer

RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery

A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases

Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer

Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis

One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults